Depending on when in the third quarter its deal with Bristol-Myers Squibb closes, this could be the last report of the beloved big biotech.
News & Analysis: Celgene
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
Looking for potential winning biotech stocks? These five check off all the boxes for investors.
Why Celgene Shareholders Should Hold On to Their Bristol-Myers Squibb Stock Once the Acquisition Closes
The fat lady is getting ready to sing with this big pharma deal. Celgene shareholders will soon have a decision to make.
Shareholder support for its proposed merger with Bristol-Myers appears back on track.
Elsewhere, the merger between Bristol-Myers Squibb and Celgene got some votes of confidence.
These stocks are dirt cheap. But perhaps not for too much longer.
This mega-merger could be on the rocks following objections by high-profile investors.
These healthcare giants are taking the word "value" to an extreme.
These three healthcare gems have the full attention of our team of experts.